Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy,...
Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy,...
賽諾菲安萬特的Frexalimab第2期數據顯示，複發性多發性硬化神經細胞損傷關鍵生物標誌物減少41％；高劑量組48周後血漿神經絲輕鏈水平顯著下降；支持其高功效的可能性，這是一種可自主使用、高效、很可能是一種全新的免疫類藥物。
Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy, Disease-Modifying Treatment; Phase 3 Studies Underway
賽諾菲安萬特的Frexalimab二期數據顯示，複發性多發性硬化症神經細胞損傷關鍵生物標誌物下降41％；高劑量組在48周後血漿神經絲輕鏈水平顯著下降；支持作爲高效治療、疾病修飾治療的潛力藥物；三期研究正在進行。
Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS
Frexalimab新的二期數據顯示，複發性多發性硬化症神經細胞損傷關鍵生物標誌物下降。
- Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain (NfL) levels, a biomarker of nerve cell damage, after 48 weeks of treatment
- Data support potential as a first-in-class, high-efficacy, and disease-modifying treatment for people with relapsing MS
- Phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS (nrSPMS) are underway
- Frexalimab高劑量組觀察到神經細胞損傷生物標誌物——血漿神經絲輕鏈（NfL）水平下降41％，治療48周後；
- 數據支持作爲首個高效、疾病修飾性治療複發性多發性硬化症的治療方法。
- Frexalimab 在複發性多發性硬化症和非複發性二級進行性多發性硬化症（nrSPMS）的三期研究正在進行中。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。